Research Article
Safety and Effectiveness of SeptimebTM in Patients with COVID-19 Referred to a Teaching and Referral Hospital: A Clinical Trial Study (Phase II)
Author(s):
Minoo Mohraz, Mohammadreza Salehi, Hamid Reza Khorram Khorshid, Nasser Aghdami, Farhad Gharibdoost, Alireza Barzegary, Zahra Pashaei and Seyed Ahmad Seyed Alinaghi*
Objectives: We conducted this study to determine the safety and evidence of
effectiveness of Septimeb TM among patients with COVID-19.
Materials and
methods: A phase II clinical trial with SeptimebTM was implemented in
Imam Khomeini Hospital as a before and after trial during May to October
2020. Considering the inclusion and exclusion criteria, 33 patients with
COVID-19 were treated using SeptimebTM. The patients received the antiinflammatory
drug 150 mg/10m l/IV infusion SeptimebTM on the irst day
and then 300 mg/20 ml/ IV infusion from the second day onwards for at least
2 days and up to 13 days based on the improvement of clinical symptoms
and laboratory indings in addition to treatment which were selected
according to the national protocol. The patients were then e.. Read More»
Select your language of interest to view the total content in your interested language
The is a monthly multidisciplinary medical journal.